In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Psivida Corp. (NASDAQ:PSDV) reported that Pfizer Inc. has picked up 1,862,093 of common stock as of 2017-05-26.
The acquisition brings the aggregate amount owned by Pfizer Inc. to a total of 1,862,093 representing less than 4.7% stake in the company.
For those not familiar with the company, pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.
A glance at Psivida Corp. (NASDAQ:PSDV)’s key stats reveals a current market capitalization of 86.96 Million based on 39.36 Million shares outstanding and a price at last close of $2.22 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2012-10-01, Hopper picked up 5,000 at a purchase price of $1.67. This brings their total holding to 10,000 as of the date of the filing.
On the sell side, the most recent transaction saw Ross unload 5,000 shares at a sale price of $4.70. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Psivida Corp. (NASDAQ:PSDV) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.